Clinicopathologic Features and Prognosis of Primary Gastrointestinal Stromal Tumor Patients under 35 Years of Age: A 10-Year Retrospective Study.
Peng Zhang,Rui Deng,Ke Liu,Xiao-Ming Shuai,Jie Bai,Wei-Long Chang,Jin-Bo Gao,Kai-Lin Cai,Guo-Bin Wang,Kai-Xiong Tao
DOI: https://doi.org/10.1002/jso.24431
2016-01-01
Journal of Surgical Oncology
Abstract:ObjectivesTo investigate gastrointestinal stromal tumor (GIST) clinicopathologic characteristics in young adults.MethodsClinicopathologic data from GIST patients under 35 years diagnosed at our hospital from January 2005 to December 2014 were retrospectively collected.ResultsThirty‐one (5.3%, 31/585) patients were included; 17 (54.8%) were female. The most common presentation and primary tumor site were gastrointestinal bleeding (n = 18, 58.1%) and the small intestine (n = 13, 41.9%), respectively. Fifteen (48.4%) GISTs were classified as having a high relapse risk; two (6.4%), intermediate; nine (29.0%), low; and five (16.1%), very low. All patients underwent tumor resection. With a median follow‐up of 51 months for 20 (64.5%) patients, 12 (60%) were given imatinib methylate as adjuvant therapy. One (5%) patient died of peritoneal GIST dissemination, four (20%) developed abdominal recurrences, two (10%) had hepatic metastasis, and thirteen (65%) were disease free. The 5‐year disease‐free survival rate was 51.2%.ConclusionsGISTs rarely occur in young adults. The most common location is the small intestine. A slight female predominance was observed in the current study. Adjuvant therapy longer than the recommended duration may be beneficial for GISTs with a high relapse risk. Combined targeted therapy and surgery is appropriate for recurrent and metastatic GISTs in select patients. J. Surg. Oncol. 2016;114:977–981. © 2016 Wiley Periodicals, Inc.